Article
Biochemistry & Molecular Biology
Marta Fortunato, Giada Amodio, Silvia Gregori
Summary: Tolerogenic dendritic cells (tolDC) play a central role in immune homeostasis and peripheral tolerance. We developed a protocol to generate genetically engineered tolDC overexpressing IL-10 (DCIL-10) and found that they can modulate cytotoxic CD8(+) T cell responses by reducing proliferation and activation, and inducing anergic CD8(+) T cells without signs of exhaustion.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Biology
Cilia R. Pothast, Romy C. Dijkland, Melissa Thaler, Renate S. Hagedoorn, Michel G. D. Kester, Anne K. Wouters, Pieter S. Hiemstra, Martijn J. van Hemert, Stephanie Gras, J. H. Frederik Falkenburg, Mirjam H. M. Heemskerk
Summary: CMV-specific T cells cross react with SARS-CoV-2, despite low sequence homology between the two viruses, and may contribute to the pre-existing immunity against SARS-CoV-2.
Article
Immunology
Atefeh Mohseninia, Parva Dehghani, Afshar Bargahi, Mazda Rad-Malekshahi, Raha Rahimikian, Ali Movahed, Mohammad Reza Farzaneh, Mohsen Mohammadi
Summary: This study presents a strategy to enhance peptide nanofibers-mounted antitumor immune response by formulating peptide nanofibers with polyethylene imine. The formulated nanofibers showed increased efficiency in uptake by antigen-presenting cells, enhanced antigen cross-presentation capacity, and the ability to induce robust antigen-specific CD8+ T cell responses. The formulation also led to maximum antitumor response in tumor-bearing mice.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Biology
Risa Ebina-Shibuya, Erin E. West, Rosanne Spolski, Peng Li, Jangsuk Oh, Majid Kazemian, Daniel Gromer, Phillip Swanson, Ning Du, Dorian B. McGavern, Warren J. Leonard
Summary: TSLP plays a crucial role in the development of diseases such as asthma, atopic dermatitis, and allergic inflammation, but its role in CD8(+) T-cell primary responses and memory CD8(+) T cell responses to secondary viral infection is still controversial. Research has shown that TSLP limits the primary CD8(+) T-cell response to influenza, but has little effect on T cell function and the number of memory CD8(+) T cells generated after influenza infection, while inhibiting memory CD8(+) T-cell responses to secondary viral infections.
Article
Biochemistry & Molecular Biology
Maha K. Rahim, Trine Line H. Okholm, Kyle B. Jones, Elizabeth E. McCarthy, Candace C. Liu, Jacqueline L. Yee, Stanley J. Tamaki, Diana M. Marquez, Iliana Tenvooren, Katherine Wai, Alexander Cheung, Brittany R. Davidson, Vrinda Johri, Bushra Samad, William E. O'Gorman, Matthew F. Krummel, Annemieke van Zante, Alexis J. Combes, Michael Angelo, Lawrence Fong, Alain P. Algazi, Patrick Ha, Matthew H. Spitzer
Summary: CD8+ T cell responses in lymph nodes play a critical role in anti-tumor immunity in human head and neck squamous cell carcinomas. These responses are associated with specific T cells in circulation and provide important insights for immune-based therapies in cancer.
Review
Immunology
Fiona Chatterjee, Stefani Spranger
Summary: Dendritic cells play a crucial role in anti-tumor immune responses by activating cytotoxic CD8(+) T cells. In addition to cross-presentation, recent studies have found that MHC-dressing can also activate CD8(+) T cells against tumor cell-derived antigens. Understanding the specific contributions of MHC-dressing to anti-tumor immunity has potential for novel therapeutic approaches.
SEMINARS IN IMMUNOLOGY
(2023)
Article
Oncology
Rebecca Harris, Mahinbanu Mammadli, Shannon Hiner, Liye Suo, Qi Yang, Jyoti Misra Sen, Mobin Karimi
Summary: Cancer immunotherapy relies on improving T cell effector functions against malignancies, but the biological functions of key transcription factors (TFs) in this process are not well understood. In this study, a murine model was utilized to investigate the role of TCF-1 in T cell response to cancer. The results showed that TCF-1 suppresses NKG2D expression on CD8 T cells and regulates critical molecules responsible for peripheral CD8 T cell effector functions.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
Philippa Meiser, Moritz A. Knolle, Anna Hirschberger, Gustavo P. de Almeida, Felix Bayerl, Sebastian Lacher, Anna-Marie Pedde, Sophie Flommersfeld, Julian Hoenninger, Leonhard Stark, Fabian Stoegbauer, Martina Anton, Markus Wirth, Dirk Wohlleber, Katja Steiger, Veit R. Buchholz, Barbara Wollenberg, Christina E. Zielinski, Rickmer Braren, Daniel Rueckert, Percy A. Knolle, Georgios Kaissis, Jan P. Boettcher
Summary: A study found that the clustering of immune cells within tumors, orchestrated by a specific type of immune cell called cDC1, is a unique feature associated with effective anti-cancer immunity. These clusters promote the activation and expansion of stem-like CD8+ T cells, which play a crucial role in cancer immune control. This finding has important implications for cancer therapy.
Article
Biochemistry & Molecular Biology
N. Balneger, L. A. M. Cornelissen, M. Wassink, S. J. Moons, T. J. Boltje, Y. E. Bar-Ephraim, K. K. Das, J. N. Sondergaard, C. Bull, G. J. Adema
Summary: The study reveals that sialic acids play a crucial role in regulating the activation and interaction of dendritic cells. Blocking sialic acids enhances the immune activation ability and antigen-induced T cell interactions of dendritic cells. These findings have important implications for understanding the mechanisms of immune responses.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2022)
Article
Immunology
Thais B. Bertolini, Jamie L. Shirley, Irene Zolotukhin, Xin Li, Tsuneyasu Kaisho, Weidong Xiao, Sandeep R. P. Kumar, Roland W. Herzog
Summary: AAV vectors are promising for gene therapy, but immune responses can occur due to CpG motifs in the vector genome, leading to CD8(+) T cell activation. Depletion of CpG motifs can reduce such immune responses.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Eunjung Cho, Seongeun Han, Hyeon Seok Eom, Sang-Jin Lee, Chungyong Han, Rohit Singh, Seon-Hee Kim, Bo-Mi Park, Byoung-Gie Kim, Young H. Kim, Byoung S. Kwon, Ki Taek Nam, Beom K. Choi
Summary: The interaction between regulatory T (Treg) cells and self-reactive T cells is crucial for maintaining immune tolerance. This study reveals that self-antigens can activate CD8(+) T cells and induce delayed proliferation of Treg cells. The P53 signaling pathway plays a critical role in this process. Understanding the mechanisms of Treg cell stimulation and its implications in autoimmune diseases and cancer immunotherapy is important.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Immunology
Jeffrey A. Tomalka, Mehul S. Suthar, Michael S. Diamond, Rafick P. Sekaly
Summary: Innate immunity is an essential defense mechanism in cells, originating from bacteria and playing key roles in pathogen defense and immune response activation. Recent studies have shown that individual exposure histories, such as prior infections, vaccinations, and microbial metabolites, can modulate innate immunity and affect its effectiveness. Understanding how environmental factors regulate innate immune responses is crucial for pandemic preparedness.
TRENDS IN IMMUNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Yuko Okuyama, Akira Okajima, Nao Sakamoto, Ayaka Hashimoto, Ryuto Tanabe, Akihisa Kawajiri, Takeshi Kawabe, Naoto Ishii
Summary: IL-33 induces an anti-tumor effect mediated by ILC2s and CD8+ T cells in tumor tissue. The interaction between ILC2s expressing OX40L and CD8+ T cells expressing OX40 promotes the activation and proliferation of CD8+ T cells, contributing to the anti-tumor effect.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2022)
Article
Chemistry, Multidisciplinary
J. Grabowska, A. J. Affandi, D. van Dinther, M. K. Nijen Twilhaar, K. Olesek, L. Hoogterp, M. Ambrosini, D. A. M. Heijnen, L. Klaase, A. Hidalgo, K. Asano, P. R. Crocker, G. Storm, Y. van Kooyk, J. M. M. den Haan
Summary: In this study, liposomes containing GM3 were shown to efficiently target CD169(+) macrophages, inducing specific immune responses including antigen-specific CD8(+) and CD4(+) T cell as well as B cell responses. Administration of GM3 liposomes containing ovalbumin resulted in delayed tumor growth and improved survival in B16-OVA tumor bearing mice. The study also highlighted the essential role of CD169(+) macrophages and cDC1s in inducing CD8(+) T cell immunity through liposomal vaccination.
JOURNAL OF CONTROLLED RELEASE
(2021)
Article
Biochemistry & Molecular Biology
Can Cui, Jiawei Wang, Eric Fagerberg, Ping-Min Chen, Kelli A. Connolly, Martina Damo, Julie F. Cheung, Tianyang Mao, Adnan S. Askari, Shuting Chen, Brittany Fitzgerald, Gena G. Foster, Stephanie C. Eisenbarth, Hongyu Zhao, Joseph Craft, Nikhil S. Joshi
Summary: The study found that the enrichment of TFH cell transcriptional signature in lung adenocarcinoma patients is correlated with GC B cell signature and prolonged survival. Interactions between tumor-specific TFH and GC B cells are crucial for tumor control and effector CD8 T cell function.
Article
Pathology
Charles Van Slambrouck, Jooryung Huh, Cheolwon Suh, Joo Y. Song, Madhu P. Menon, Aliyah R. Sohani, Amy S. Duffield, Reva C. Goldberg, Paola Dama, Kazuma Kiyotani, James Godfrey, Carrie Fitzpatrick, Justin Kline, Sonali M. Smith, Elaine S. Jaffe, Sylvia Hartmann, Girish Venkataraman
Article
Hematology
Nicole A. Carreau, Philippe Armand, Reid W. Merryman, Ranjana H. Advani, Michael A. Spinner, Alex F. Herrera, Radhakrishnan Ramchandren, Muhammad S. Hamid, Sarit Assouline, Raoul Santiago, Nina Wagner-Johnston, Suman Paul, Jakub Svoboda, Steven M. Bair, Stefan K. Barta, Sunita Nathan, Reem Karmali, Pallawi Torka, Kevin David, Frederick Lansigan, Daniel Persky, James Godfrey, Julio C. Chavez, Yuhe Xia, Catherine Diefenbach
BRITISH JOURNAL OF HAEMATOLOGY
(2020)
Article
Oncology
Reid W. Merryman, Nicole A. Carreau, Ranjana H. Advani, Michael A. Spinner, Alex F. Herrera, Robert Chen, Sarah Tomassetti, Radhakrishnan Ramchandren, Muhammad Hamid, Sarit Assouline, Raoul Santiago, Nina Wagner-Johnston, Suman Paul, Jakub Svoboda, Steven M. Bair, Stefan K. Barta, Yang Liu, Sunita Nathan, Reem Karmali, Madelyn Burkart, Pallawi Torka, Kevin A. David, Catherine Wei, Frederick Lansigan, Lukas Emery, Daniel Persky, Sonali M. Smith, James Godfrey, Julio Chavez, Jonathan B. Cohen, Andrea B. Troxel, Catherine Diefenbach, Philippe Armand
Article
Oncology
Nicole A. Carreau, Orrin Pail, Philippe Armand, Reid Merryman, Ranjana H. Advani, Michael A. Spinner, Alex Herrera, Robert Chen, Sarah Tomassetti, Radhakrishnan Ramchandren, Muhammad S. Hamid, Sarit Assouline, Raoul Santiago, Nina Wagner-Johnston, Suman Paul, Jakub Svoboda, Steven Bair, Stefan Barta, Yang Liu, Sunita Nathan, Reem Karmali, Madelyn Burkart, Pallawi Torka, Kevin David, Catherine Wei, Frederick Lansigan, Lukas Emery, Daniel Persky, Sonali Smith, James Godfrey, Julio Chavez, Yuhe Xia, Andrea B. Troxel, Catherine Diefenbach
Letter
Hematology
Jonathan A. Trujillo, James Godfrey, Yifei Hu, Jun Huang, Sonali M. Smith, Matthew J. Frigault, Zachariah DeFilipp, Daniel Appelbaum, Yonglin Pu, Nicholas Feinberg, Thomas Althaus, Michael R. Bishop, Peter A. Riedell, Justin Kline
Article
Cell Biology
Xiufen Chen, Brendan W. MacNabb, Blake Flood, Bruce R. Blazar, Justin Kline
Summary: Research has found that CD8(+) T cells targeting cancer can exhibit different tolerant states when encountering tumor antigens, potentially mediated by different pathways.
Article
Oncology
Swetha Kambhampati, Matthew G. Mei, James Godfrey, Tanya Siddiqi, Amandeep Salhotra, Robert Chen, Eileen Smith, Leslie L. Popplewell, Alex F. Herrera
Summary: This retrospective study investigated the efficacy and safety of PD-1 blockade in relapsed refractory classical Hodgkin lymphoma patients who had previously received avelumab treatment. The results showed that PD-1 blockade was effective in the majority of patients, with a durable response observed and no significant increase in adverse events.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)
Article
Hematology
James Godfrey, Hongtao Liu, Jovian Yu, Michael Tallarico, Emily Curran, Andrew Artz, Peter A. Riedell, Wendy Stock, Theodore Karrison, Carrie Fitzpatrick, Girish Venkataraman, Alan Cooper, Sonali M. Smith, Michael R. Bishop, Justin Kline
Summary: This study evaluates the safety and efficacy of pembrolizumab in patients experiencing relapse after alloHCT. The results suggest that pembrolizumab treatment shows a certain level of effectiveness in relapsed lymphoid malignancies, although it can induce severe immune-related adverse events that require vigilant monitoring.
Article
Hematology
Joo Y. Song, Mary Nwangwu, Ting-Fang He, Weiwei Zhang, Hany Meawad, Victoria Bedell, Joyce Murata-Collins, Pamela Skrabek, Michel R. Nasr, David Scott, James Godfrey, Peter Lee, Wing C. Chan, Dennis D. Weisenburger, Anamarija M. Perry, Alex F. Herrera
Summary: The tumor microenvironment (TME) plays a crucial role in the development and prognosis of lymphomas, particularly diffuse large B-cell lymphoma (DLBCL). This study utilized multispectral immunofluorescence to investigate the cellular composition of T-cell subsets, macrophages, and natural killer cells in DLBCL patients treated with R-CHOP chemotherapy. The results showed that patients with a low T-cell proportion in the TME had a poor survival, suggesting immune escape mechanisms.
Review
Immunology
Brendan W. MacNabb, Ellen V. Rothenberg
Summary: T-cell differentiation is a regulated developmental process controlled by transcription factors and chromatin landscapes, and influenced by signals from the thymic stroma. Differentiation is driven by changing combinations of TFs and involves multiple checkpoints. Fetal T-cell development differs from adult and involves unique populations of innate lymphoid cells and invariant gamma delta T cells. Recent single-cell transcriptome data provide insights into the TF networks involved in T-cell differentiation in the fetal and adult mouse thymus.
IMMUNOLOGICAL REVIEWS
(2023)
Article
Hematology
Matthew Mei, Lu Chen, James Godfrey, Joo Song, Colt Egelston, Sandrine Puverel, Elizabeth Budde, Saro Armenian, Liana Nikolaenko, Mary Nwangwu, Weihua Guo, Lei Gao, Peter Lee, Robert Chen, Shari Daniels, Neena Kennedy, Lacolle Peters, Jasmine Zain, Steven Rosen, Stephen Forman, Leslie Popplewell, Larry Kwak, Alex F. Herrera
Summary: This phase 1 study evaluated the addition of vorinostat to pembrolizumab in patients with follicular lymphoma. The study found that the combination therapy had a high overall response rate in patients with relapsed classical Hodgkin's lymphoma.
Article
Hematology
Ajay Major, Jovian Yu, Navika Shukla, Yan Che, Theodore G. Karrison, Rachel Treitman, Manali K. Kamdar, Bradley M. Haverkos, James Godfrey, Melissa A. Babcook, Timothy J. Voorhees, Sophie Carlson, Daria Gaut, Caspian Oliai, Jason T. Romancik, Allison M. Winter, Brian T. Hill, Radhika Bansal, Jose C. Villasboas Bisneto, Imran A. Nizamuddin, Reem Karmali, Lindsey A. Fitzgerald, Deborah M. Stephens, Priyanka A. Pophali, Asaad Trabolsi, Jonathan H. Schatz, Marie Hu, Veronika Bachanova, Michael J. Slade, Nathan Singh, Naushee Ahmed, Joseph P. McGuirk, Michael R. Bishop, Peter A. Riedell, Justin Kline
Summary: Checkpoint inhibitor therapy with anti-PD-1 antibodies is not effective as a salvage strategy for most patients after CAR-T, particularly among those relapsing early after CAR-T. Alternative approaches are needed to improve post-CAR-T outcomes.
Article
Oncology
James Godfrey, Xiufen Chen, Nicole Sunseri, Alan Cooper, Jovian Yu, Arina Varlamova, Dmitry Zarubin, Yuriy Popov, Connor Jacobson, Ekaterina Postovalova, Zhongmin Xiang, Krystle Nomie, Aleksander Bagaev, Girish Venkataraman, Yuanyuan Zha, Sravya Tumuluru, Sonali M. Smith, Justin P. Kline
Summary: This study reveals that TIGIT is widely expressed in lymphoma-infiltrating T cells (LITs) and frequently coexpressed with PD-1. In DLBCL, TIGIT(+) LITs often have significant contact with malignant B cells and exhibit dysfunctional cytokine production upon restimulation. In mouse experiments, combined blockade of PD-1 and TIGIT leads to complete rejection of lymphomas and significantly prolongs survival compared to monoblockade therapy.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)